Cancer Trials Inappropriately Excluded

This is a news story, published by ScienceDaily, that relates primarily to Duffy news.

disease research news

For more disease research news, you can click here:

more disease research news

ScienceDaily news

For more news from ScienceDaily, you can click here:

more news from ScienceDaily

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like disease research news, you might also like this article about

blood neutrophil count

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest benign ethnic neutropenia news, natural blood test variability news, disease research news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

blood neutrophil counts

ScienceDaily

•

Clinical trials inappropriately excluding people of African/Middle Eastern descent, new research shows

Summary

Nutrition label

80% Informative

People of African /Middle Eastern descent at a disadvantage due to natural blood test variability, study finds.

Tests restrict clinical trial eligibility to patients with certain blood levels of neutrophils may be unfairly discriminating against patients who could potentially benefit from trial therapies.

Tests that restrict trial eligibility may also call for less-effective doses for some individuals, researchers say.

Neutrophil criteria for clinical trials and dose modifications are a hidden contributor to inequity that can be rectified.

Follow-up studies are needed to determine if administering full doses to people with Duffy -null patients are safe and effective.

The study was funded by the National Institutes of Health , the American Society for Clinical Oncology , and the Wellcome Trust .

VR Score

Informative language

Neutral language

Article tone

formal

Language

English

Language complexity